J9353 Margetuximab-cmkb - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Margetuximab-cmkb

Brand Name:

Margenza

Strength:

5mg

HCPCS:

J9353

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

HER2

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

July 23, 2021

CMS Discontinuation Date:

Status:

In Use